CureVac AG :
Curevac is a private German mRNA company with a diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19) provides further technology validation. Other companies in the space: MRNA, TBIO, BNTX.
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
Ph1 readout mid-2021
Ph2 initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
Ph1 readout mid-2021
Ph2 initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Autoimmune, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany
Tübingen, Baden-Wurttemberg 72076
Germany
Presentation:
Company Participants at 2020 Wall Street "On Tap"
Franz-Werner Haas
CureVac AG, Acting Chief Executive Officer, Chief Operating Officer
Franz-Werner Haas joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions.
Franz-Werner started his professional career as an assistant to the management of a privately-held holding company before assuming several management positions in the Life Science Industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, K.U. Leuven and the University of Edinburgh (LL.M.).
More info:
My account:
Upcoming Company Event Participation
2020 Wall Street "On Tap"
Virtual,
October 1, 2020
Top 10 Holders of CureVac N.V.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Apo Asset Management GmbH | 0.01 | 15,300 | 0.67 | Funds | 8/31/20 |
| Bellevue Asset Management AG | 0.01 | 14,000 | 0.62 | Funds | 8/31/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.